In 2015, US$202 million was invested in cure research, a substantial 25 percent increase over 2014 investment. The bulk of investment came from the public sector, with US$18 million disbursed by various philanthropies such as amfAR, CANFAR, the Fair Foundation, the BMGF and Wellcome Trust. Several companies are known to have active cure research programs but this analysis was only able to obtain information from one commercial entity and thus the estimate undercounts commercial-sector contributions.
Various initiatives were ongoing in 2015. These include: a revised International AIDS Society Global Scientific Strategy for Towards a Cure; a new collaboration at the NIH to support cure strategies; a six-year series of investments by amfAR for discovering a broadly applicable cure; and the start of trials involving data on early immune responses and viral reservoirs in early infections.